ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Treatment A: BGF MDI HFO

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by AstraZeneca.

Furthest: phase 1, since Oct 4, 20222 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca20 open or runningphase 1since Oct 4, 2022Oct 4, 2022none ahead

Also a collaborator on its studies: Parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 4, 2022First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05569421 · 108 enrolled · United States
  2. Dec 4, 2024Phase 1 study in AsthmaNCT06723756 · 105 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06723756Asthma · United States1CompletedJun 1, 2025105
NCT05569421Pulmonary Disease, Chronic Obstructive · United States1CompletedApr 14, 2023108

How it is read

Names in the registry

  • “Treatment A: BGF MDI HFO”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.